Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD39


Brief Information

Name:Ectonucleoside triphosphate diphosphohydrolase 1
Target Synonym:CD39 Antigen,CD39,EC,NTPDase-1,NTPDase 1,ATPDase,SPG64,EC:,Ecto-ATPase 1,Lymphoid cell activation antigen,ENTPD1,Ectonucleoside Triphosphate Diphosphohydrolase 1,Ecto-ATPDase 1,Ecto-Apyrase,Ecto-ATP diphosphohydrolase 1,EC 3.6.1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Biotinylated Human CD39 (R138A, M139A, E142K) Protein, His,Avitag (Cat. No. CD9-H82E8) at 1 μg/mL (100 μL/well)on streptavidin precoated (Cat. No. STN-N5116) (0.5 μg/well) plate can bind Anti-CD39 Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

CD39 MALS images

The purity of Cynomolgus CD39 Protein, His Tag (Cat. No. CD9-C5PH3) is more than 85% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.

Synonym Name

CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1


CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms,  a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TTX-030 TTX-030 Phase 2 Clinical Adimab LLC Solid tumours; Pancreatic Neoplasms; Lymphoma Details
IPH-5201 IPH-5201 Phase 2 Clinical Inserm, Orega Biotech Solid tumours; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Perenostobart SRF-617 Phase 2 Clinical Surface Oncology Inc Solid tumours; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
JS-019 JS-019 Phase 1 Clinical Beijing Enrini Biotechnology Co Ltd Solid tumours; Lymphoma Details
ES-014 ES-014 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours; Neoplasms; Neoplasm Metastasis Details
PUR-001 PUR-001 Phase 1 Clinical Purinomia Biotech Inc Solid tumours Details
AB-598 AB598 Phase 1 Clinical Arcus Biosciences Inc Ovarian Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Eurestobart ES-002023 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours Details
ES-002 ES-002 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message